Biocon gets Health Canada nod for Bosaya & Vevzuo biosimilars

Biocon Ltd has received Health Canada approval for Bosaya™ (denosumab), a biosimilar to Prolia®, and Vevzuo™ (denosumab), a biosimilar to Xgeva®, on April 3, 2026. This approval expands Biocon's access to high-quality biosimilars in key global markets. Bosaya™ is approved for treating osteoporosis in various patient groups, while Vevzuo™ targets skeletal-related events in patients with multiple myeloma and bone metastases from solid tumours, as well as giant cell tumour of bone. The approvals are based on comprehensive analytical, nonclinical, and clinical data, demonstrating high similarity to the reference products with no clinically meaningful differences in quality, safety, or efficacy. This strengthens Biocon's portfolio of affordable biologic therapies across immunology and oncology, potentially benefiting over 2 million adults with osteoporosis and hundreds of cancer patients annually.